The quiet catalyst: Why open-label extension trials matter for ASX biotechs

While main trial results tend to attract the big headlines for biotech companies, lower-profile open-label extension (OLE) trials can tell an equally important story.

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.themercury.com.au)